Peerview Internal Medicine Cme/cne/cpe Audio Podcast

Go online to PeerView.com/KKF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with cancer often present to the ED in an acutely ill state with complications from their cancer or treatments used, but a broadening use of a new class of cancer immunotherapies has changed the types of complications experienced by these patients. This spectrum of unique toxicities, termed immune-related adverse events (irAEs), is less well known, and commonly, they are overlooked, misdiagnosed, and not appropriately managed in ED settings. Standard algorithms for diagnosis and treatment no longer apply, as irAEs require a distinct approach. Are you prepared to handle the new category of oncologic emergencies you are likely to increasingly encounter in your ED? This activity will help you get up to date and change your practice. Emergency medicine and oncology experts will join forces to provide practical, case-based guidance for timely and accurate recognition, triage

Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fix

Go online to PeerView.com/TGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the multidisciplinary relationship between urologic oncologists and advanced practice clinicians in the management of patients with prostate cancer has become increasingly more important in providing the best patient care. During this video, an expert panel highlights how a multidisciplinary team can use the latest clinical evidence, treatment guidelines, and expert consensus recommendations to improve care for patients with prostate cancer and gives practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. The experts also provide meaningful guidance to assist clinicians in optimizing treatment planning based on a modern understanding of prostate cancer biology, best treatment practices, and the expanding opportunities for treatment personalization across the disease contin

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient’s ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuvant, or perioperative immunotherapy in early-stage cancers, key trials and relevant endpoints, and evolving evidence supporting ICI use in different early-stage solid tumors, Implement best practices for multidisciplinary/interprofessional patient and tumor evaluation as well as coordination of care when managing patients with early-stage cancers, Integrate immunotherapies into individualized, multimodal treatment plans for appropriate patients with early-stage cancers in clinical practice or through clinical trial partici

Go online to PeerView.com/AYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts will review the presentation and diagnosis of AD and discuss the current evidence and guidelines for treatment selection for pediatric and adult patients. The faculty will also offer their thoughts on engaging with patients to provide personalized care and improved outcomes. Learn from the data and the experts in this informative, engaging discussion. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD), Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines, Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would

Go online to PeerView.com/XZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent validation of novel multitargeted TKIs and immune checkpoint inhibitor therapies in metastatic disease, the treatment horizon of renal cell carcinoma (RCC) has vastly expanded and has continued to broaden with the emergence of long-term data supporting the efficacy of dual checkpoint blockade and combination therapies involving immunotherapy/TKI partners. Despite recent regulatory approvals, guideline updates, and abundant evidence, many medical and urologic oncologists find it challenging to bring these novel immune and targeted strategies into clinical practice. Designed to bridge the gap between theory and practice, this educational activity features expert guidance on how oncologists and urologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety

Go online to PeerView.com/ZWH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite a widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, there has been unequal progress with increasing access to treatment and reducing the number of new HIV infections and AIDS-related deaths, resulting in several vulnerable populations being left behind. Stigma and discrimination, together with other social inequalities and exclusion, are proving to be key barriers in battling this epidemic. In this activity, based on a recent live web broadcast, provider and patient perspectives on overcoming barriers to modern HIV treatment strategies will be examined. Additionally, the engaging panel will discuss the importance of establishing strong patient–provider relationships and demonstrating an understanding of the unique challenges faced by each individual patient living with HIV. Upon completion of this CE activity, parti

Go online to PeerView.com/FFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome, Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment, Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome, Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.

Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies in the adjuvant and neoadjuvant settings are under way as well. How should these advances be transitioned to the clinic based on the accumulating supportive evidence? How can surgeons and oncologists work together to ensure proper risk assessment and treatment planning to improve outcomes in patients with HR+/HER2- EBC? This PeerView Virtual Workshop provides pertinent updates on the most recent research and available evidence on CDK4 and 6 inhibition in HR+/HER2- EBC, as well as practical, case-based guidance on the applic

Go online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestations. These experts provide practical guidance on strategies and techniques for diagnosing, staging, and managing patients who present with various cardiac irAEs. This virtual session will engage participants with opportunities to participate in consultative assessments of real-world patient cases, including contributing to key aspects of diagnostic decision-making and deliberation of optimal strategies for collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Sum

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be disc

Go online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease continuum. Hear an in-depth conversation on how the HCC management team can successfully collaborate to offer the best possible care to their patients. Upon completion of this CE activity, participants will be better able to: Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC, Review ongoing clinical trials and

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numero

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants wil

Go online to PeerView.com/KPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid progress in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has practice-changing implications for pathologists, oncologists, and the broader multidisciplinary lung cancer care team. In addition to multiple targeted therapy options available for patients with metastatic NSCLC with more commonly occurring EGFR mutations, new agents have recently been approved by the FDA for those with less common but highly important EGFR exon 20 insertion mutations. Furthermore, EGFR-targeted therapy is now also transitioning from the advanced to early-stage settings of lung cancer, with the first regulatory approval granted for adjuvant therapy so far, and further developments are anticipated. The expansion of the treatment arsenal means that appropriate biomarker testing is increasingly more important, including the selection and use of correct testing methodologies to i

Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a

Go online to PeerView.com/KHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies. Upon completion of this accredited CE activity, participants should be better able to: Discuss key limitations associated with current treatment approaches for managing food allergies, Differentiate the mechanisms of action of current and emerging treatments for IgE-mediated food allergies, Identify patients with IgE-mediated food allergies who would likely derive benefit from treatment with IgE-blocking therapies.

Go online to PeerView.com/AMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance. Upon completion of this CE activity, participants will be able to: Summarize the mechanistic and selectivity differences among covalent and noncovalent BTK inh

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatme